Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Crossover Study of LY3454738 in Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines
2019-002495-13Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ucenprubart in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in UAS7 score from baseline to Week 12 in Period 2. Started Nov 2019; status: terminated.
02
Drugs
ucenprubart
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2019-002495-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002495-13.